Upregulation of peptide transporters PEPT1 and PEPT2 by Janus kinase JAK2

Cellular Physiology and Biochemistry

Volumn 31, Issue 4-5, 2013, Pages 673-682

  Hosseinzadeh, Zohreh ^a   Dong, Luo ^a   Bhavsar, Shefalee K ^a   Warsi, Jamshed ^a   Almilaji, Ahmad ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Energy depletion; Intestine; JAK2 inhibitor AG490; Nutrient transport; Peptide transport

Indexed keywords

COMPLEMENTARY RNA; DIPEPTIDE; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; BREFELDIN A;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRODE; ENZYME INHIBITION; FEMALE; NONHUMAN; OOCYTE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VOLTAGE CLAMP; WILD TYPE; XENOPUS; CELL MEMBRANE; GAIN OF FUNCTION MUTATION; PROTEIN STABILITY; VOLTAGE CLAMP TECHNIQUE;

EID: 84878421247     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350086     Document Type: Article

References (57)

1. Noon-Song EN, Ahmed CM, Dabelic R, Canton J, Johnson HM: Controlling nuclear JAKs and STATs for specific gene activation by IFNgamma. Biochem Biophys Res Commun 2011;410:648-653.
2. Spivak JL: Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med 2010;152:300-306.
3. Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, Thomas D, Ramshaw HS, Stomski F, Perugini M, D'Andrea R, Grimbaldeston M, Parker MW: Molecular basis of cytokine receptor activation. IUBMB Life 2010;62:509-518.
4. Morris DL, Rui L: Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009;297:E1247-E1259.
5. Yang N, Jiang J, Deng L, Waters MJ, Wang X, Frank SJ: Growth hormone receptor targeting to lipid rafts requires extracellular subdomain 2. Biochem Biophys Res Commun 2010;391:414-418.
6. Brooks AJ, Waters MJ: The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010;6:515-525.
7. Kurdi M, Booz GW: JAK redux: a second look at the regulation and role of JAKs in the heart. Am J Physiol Heart Circ Physiol 2009;297:H1545-H1556.
8. Garnovskaya MN, Mukhin YV, Vlasova TM, Raymond JR: Hypertonicity activates Na+/H+ exchange through Janus kinase 2 and calmodulin. J Biol Chem 2003;278:16908-16915. (Pubitemid 36799563)
9. Gatsios P, Terstegen L, Schliess F, Haussinger D, Kerr IM, Heinrich PC, Graeve L: Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock. J Biol Chem 1998;273:22962-22968. (Pubitemid 28417472)
10. Shen XL, Wei W, Xu HL, Zhang MX, Qin XQ, Shi WZ, Jiang ZP, Chen YJ, Chen FP: JAK2V617F/STAT5 signaling pathway promotes cell proliferation through activation of Pituitary Tumor Transforming Gene 1 expression. Biochem Biophys Res Commun 2010;398:707-712.
11. Venkitachalam S, Chueh FY, Yu CL: Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene. Biochem Biophys Res Commun 2012;417:1058-1062.
12. Yao X, Balamurugan P, Arvey A, Leslie C, Zhang L: Heme controls the regulation of protein tyrosine kinases Jak2 and Src. Biochem Biophys Res Commun 2010;403:30-35.
13. Mahfouz RA, Hoteit R, Salem Z, Bazarbachi A, Mugharbel A, Farhat F, Ziyadeh A, Ibrahim A, Taher A: JAK2 V617F Gene Mutation in the Laboratory Work-Up of Myeloproliferative Disorders: Experience of a Major Referral Center in Lebanon. Genet Test Mol Biomarkers 2011;15:263-265.
14. Santos FP, Verstovsek S: JAK2 inhibitors: What's the true therapeutic potential? Blood Rev 2011;25:53-63.
15. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A: JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011;25:218-225.
16. Baskin R, Majumder A, Sayeski PP: The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. Curr Med Chem 2010;17:4551-4558.
17. Ho K, Valdez F, Garcia R, Tirado CA: JAK2 Translocations in hematological malignancies: Review of the literature. J Assoc Genet Technol 2010;36:107-109.
18. Oh ST, Gotlib J: JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol 2010;3:323-337.
19. Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
20. Hosseinzadeh Z, Shojaiefard M, Bhavsar SK, Lang F: Up-regulation of the betaine/GABA transporter BGT1 by JAK2. Biochem Biophys Res Commun 2012;420:172-177.
21. Shojaiefard M, Hosseinzadeh Z, Bhavsar SK, Lang F: Downregulation of the creatine transporter SLC6A8 by JAK2. J Membr Biol 2012;245:157-163.
22. Hosseinzadeh Z, Bhavsar SK, Shojaiefard M, Saxena A, Merches K, Sopjani M, Alesutan I, Lang F: Stimulation of the glucose carrier SGLT1 by JAK2. Biochem Biophys Res Commun 2011;408:208-213.
23. Bhavsar SK, Hosseinzadeh Z, Merches K, Gu S, Broer S, Lang F: Stimulation of the amino acid transporter SLC6A19 by JAK2. Biochem Biophys Res Commun 2011;414:456-461.
24. Hosseinzadeh Z, Bhavsar SK, Sopjani M, Alesutan I, Saxena A, Dermaku-Sopjani M, Lang F: Regulation of the glutamate transporters by JAK2. Cell Physiol Biochem 2011;28:693-702.
25. Inoue M, Terada T, Okuda M, Inui K: Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett 2005;230:72-80. (Pubitemid 41506962)
26. Rubio-Aliaga I, Daniel H: Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 2008;38:1022-1042.
27. Ingersoll SA, Ayyadurai S, Charania MA, Laroui H, Yan Y, Merlin D: The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2012;302:G484-G492.
28. Rexhepaj R, Rotte A, Pasham V, Gu S, Kempe DS, Lang F: PI3 kinase and PDK1 in the regulation of the electrogenic intestinal dipeptide transport. Cell Physiol Biochem 2010;25:715-722.
29. Rexhepaj R, Dermaku-Sopjani M, Gehring EM, Sopjani M, Kempe DS, Foller M, Lang F: Stimulation of electrogenic glucose transport by glycogen synthase kinase 3. Cell Physiol Biochem 2010;26:641-646.
30. Boehmer C, Palmada M, Klaus F, Jeyaraj S, Lindner R, Laufer J, Daniel H, Lang F: The peptide transporter PEPT2 is targeted by the protein kinase SGK1 and the scaffold protein NHERF2. Cell Physiol Biochem 2008;22:705-714.
31. Pieri M, Christian HC, Wilkins RJ, Boyd CA, Meredith D: The apical (hPepT1) and basolateral peptide transport systems of Caco-2 cells are regulated by AMP-activated protein kinase. Am J Physiol Gastrointest Liver Physiol 2010;299:G136-G143.
32. Yarandi SS, Hebbar G, Sauer CG, Cole CR, Ziegler TR: Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition 2011;27:269-275.
33. Alteheld B, Evans ME, Gu LH, Ganapathy V, Leibach FH, Jones DP, Ziegler TR: Alanylglutamine dipeptide and growth hormone maintain PepT1-mediated transport in oxidatively stressed Caco-2 cells. J Nutr 2005;135:19-26. (Pubitemid 40094315)
34. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN: Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997;17:2497-2501. (Pubitemid 27175130)
35. Dermaku-Sopjani M, Sopjani M, Saxena A, Shojaiefard M, Bogatikov E, Alesutan I, Eichenmuller M, Lang F: Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem 2011;28:251-258.
36. Strutz-Seebohm N, Pusch M, Wolf S, Stoll R, Tapken D, Gerwert K, Attali B, Seebohm G: Structural basis of slow activation gating in the cardiac I Ks channel complex. Cell Physiol Biochem 2011;27:443-452.
37. Alesutan I, Sopjani M, Dermaku-Sopjani M, Munoz C, Voelkl J, Lang F: Upregulation of Na-coupled glucose transporter SGLT1 by Tau tubulin kinase 2. Cell Physiol Biochem 2012;30:458-465.
38. Henrion U, Zumhagen S, Steinke K, Strutz-Seebohm N, Stallmeyer B, Lang F, Schulze-Bahr E, Seebohm G: Overlapping cardiac phenotype associated with a familial mutation in the voltage sensor of the KCNQ1 channel. Cell Physiol Biochem 2012;29:809-818.
39. Eckey K, Strutz-Seebohm N, Katz G, Fuhrmann G, Henrion U, Pott L, Linke WA, Arad M, Lang F, Seebohm G: Modulation of human ether a gogo related channels by CASQ2 contributes to etiology of catecholaminergic polymorphic ventricular tachycardia (CPVT). Cell Physiol Biochem 2010;26:503-512.
40. Hosseinzadeh Z, Bhavsar SK, Lang F: Downregulation of ClC-2 by JAK2. Cell Physiol Biochem 2012;29:737-742.
41. Pathare G, Foller M, Daryadel A, Mutig K, Bogatikov E, Fajol A, Almilaji A, Michael D, Stange G, Voelkl J, Wagner CA, Bachmann S, Lang F: OSR1-Sensitive Renal Tubular Phosphate Reabsorption. Kidney Blood Press Res 2012;36:149-161.
42. Daniel H, Kottra G: The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 2004;447:610-618. (Pubitemid 38241445)
43. Thwaites DT, Anderson CM: H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol 2007;92:603-619. (Pubitemid 47024940)
44. Kamal MA, Keep RF, Smith DE: Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet 2008;23:236-242.
45. Anderson CM, Thwaites DT: Hijacking solute carriers for proton-coupled drug transport. Physiology (Bethesda ) 2010;25:364-377.
46. Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ: An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 1998;58:519-525. (Pubitemid 28087417)
47. Meredith D: Review. The mammalian proton-coupled peptide cotransporter PepT1: sitting on the transporter-channel fence? Philos Trans R Soc Lond B Biol Sci 2009;364:203-207.
48. Foley DW, Rajamanickam J, Bailey PD, Meredith D: Bioavailability through PepT1: the role of computer modelling in intelligent drug design. Curr Comput Aided Drug Des 2010;6:68-78.
49. Newstead S: Towards a structural understanding of drug and peptide transport within the proton-dependent oligopeptide transporter (POT) family. Biochem Soc Trans 2011;39:1353-1358.
50. Brandsch M: Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol 2009;5:887-905.
51. Nakamura T, Yamamori M, Sakaeda T: Pharmacogenetics of intestinal absorption. Curr Drug Deliv 2008;5:153-169. (Pubitemid 351977879)
52. Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A: Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. Eur J Pharm Sci 2010;40:202-208.
53. Tsume Y, Hilfinger JM, Amidon GL: Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm 2008;5:717-727.
54. Tai W, Chen Z, Cheng K: Expression Profile and Functional Activity of Peptide Transporters in Prostate Cancer Cells. Mol Pharm 2013;10:477-487.
55. Gong TW, Meyer DJ, Liao J, Hodge CL, Campbell GS, Wang X, Billestrup N, Carter-Su C, Schwartz J: Regulation of glucose transport and c-fos and egr-1 expression in cells with mutated or endogenous growth hormone receptors. Endocrinology 1998;139:1863-1871. (Pubitemid 28513847)
56. Yokota I, Hayashi H, Matsuda J, Saijo T, Naito E, Ito M, Ebina Y, Kuroda Y: Effect of growth hormone on the translocation of GLUT4 and its relation to insulin-like and anti-insulin action. Biochim Biophys Acta 1998;1404:451-456. (Pubitemid 28470546)
57. Coaxum SD, Garnovskaya MN, Gooz M, Baldys A, Raymond JR: Epidermal growth factor activates Na+/H+ exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin. Biochim Biophys Acta 2009;1793:1174-1181.